跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
NSI-1
首页
药物
NSI-1
NSI-1
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Use of benzylpiperazine-aminopyridine agents for effective treatment of depression in patients with learning and/or memory impairment or certain EEG characteristics
申请人: OUTOT NEUROSCIENCE INC
优先权: 2022
CN
Effective treatment of depression in patients having impaired learning and/or memory or certain EEG characteristics with a benzylpiperazine-aminopyridine agent
申请人: ALTO NEUROSCIENCE INC
优先权: 2024
US
2 件公开
Effective treatment of depression in patients having impaired learning and/or memory or certain EEG characteristics with a benzylpiperazine-aminopyridine agent
申请人: ALTO NEUROSCIENCE INC
优先权: 2024
US
2 件公开
Silicon compound and method of manufacturing integrated circuit device using the same
申请人: SAMSUNG ELECTRONICS CO LTD
优先权: 2022
US
2 件公开
Fusion protein construct and method for inducing HIV-specific serum IgG and secretory IgA antibodies in-vivo
申请人: CHILDRENS MEDICAL CENTER
优先权: 2003
US
2 件公开
METHOD OF TREATMENT OF DEPRESSED PATIENTS WITH POOR COGNITION AND SELECTION OF OTHER PATIENTS BENEFITING FROM A BENZYLPIPERAZINE-AMINOPYRIDINE AGENT
申请人: ALTO NEUROSCIENCE INC
优先权: 2025
US
Methods of treating depression patients with poor cognitive function and choices for other patients that benefit from benzylpiperazine-aminopyridine agents
申请人: OUTOT NEUROSCIENCE INC
优先权: 2021
CN
HAIR CARE COMPOSITION COMPRISING ALKYL-MODIFIED SILOXANE
申请人: MURRAY ANDREW MALCOLM
优先权: 2010
US
药物
反馈